Raymond Woosley - Arca Biopharma Director

ABIO
 Stock
  

USD 2.06  0.08  3.74%   

  Director
Dr. Raymond L. Woosley, M.D., Ph.D. was appointed as Director of ARCA biopharma, Inc., effective July 26, 2013. Dr. Woosley is currently the President, Emeritus, of the Critical Path Institute, a nonprofit, publicprivate partnership with the United States Food and Drug Administration, of which he was a founder, and where he served as President, Chief Executive Officer and Chairman of the Board from 2005 to 2011. Since 2012, Dr. Woosley is also the President and Chairman of the Board of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit research and education organization dedicated to the safe use of medicines. Since 2001, Dr. Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and Professor, Emeritus, since 2012, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002. From 1988 to 2000, Dr. Woosley was a professor of pharmacology and medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994
Age: 71  Director Since 2013  Ph.D    
720 940 2200  https://www.arcabio.com
Woosley earned his Ph.D. in Pharmacology from the University of Louisville, and his M.D. from the University of Miami.

Arca Biopharma Management Efficiency

Arca Biopharma has return on total asset (ROA) of (19.25) % which means that it has lost $19.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (32.49) %, meaning that it created substantial loss on money invested by shareholders. Arca Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 460 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Arca Biopharma has a current ratio of 18.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arca Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Arca Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arca Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arca Biopharma to invest in growth at high rates of return. When we think about Arca Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Khim SirithawichaiAdvanced Info Svc
2010
Ernesto VelascoAmerica Movil SAB
2007
David MunozAmerica Movil SAB
2000
Andrew LudwickZebra Technologies
2008
Honesti BasyirPT Telekomunikasi Indonesia
2015
Luis KuriAmerica Movil SAB
2000
Edwin AristiawanPT Telekomunikasi Indonesia
2019
Carlos HeluAmerica Movil A
2015
Alejandro JimenezAmerica Movil SAB
N/A
Robert DexterBCE Inc
2014
Alejandro JimenezAmerica Movil A
N/A
Olaf SwanteeTeliasonera Ab Ord
2016
Richard KeyserZebra Technologies
2008
Wichian MektrakanAdvanced Info Svc
2014
Sheila MurrayBCE Inc
2020
Monique LerouxBCE Inc
2016
Angel GuerreroAmerica Movil A
2012
Carlos GutierrezAmerica Movil SAB
2004
Edi WitjaraPT Telekomunikasi Indonesia
2020
Anna SettmanTeliasonera Ab Ord
2016
Gerardo AblazaAdvanced Info Svc
2017
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. Arca Biopharma (ABIO) is traded on NASDAQ Exchange in USA and employs 17 people.

Arca Biopharma Leadership Team

Elected by the shareholders, the Arca Biopharma's board of directors comprises two types of representatives: Arca Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arca Biopharma. The board's role is to monitor Arca Biopharma's management team and ensure that shareholders' interests are well served. Arca Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arca Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Ozeroff, Sr. VP, General Counsel and Secretary
Raymond Woosley, Director
Brian Selby, Chief Accounting Officer and VP of Fin.
Thomas Keuer, COO
Daniel Mitchell, Director
Robert Conway, Chairman of the Board
Linda Grais, Lead Independent Director
Anders Hove, Director
Michael Bristow, President CEO, Director

Arca Biopharma Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arca Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arca Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arca Biopharma's short interest history, or implied volatility extrapolated from Arca Biopharma options trading.

Pair Trading with Arca Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arca Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arca Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arca Biopharma

+0.73HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr
The ability to find closely correlated positions to Arca Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arca Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arca Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arca Biopharma to buy it.
The correlation of Arca Biopharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arca Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arca Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arca Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.